Clinical experience with BIAsp 30: Results from the Indonesian cohort of the international A1chieve study
Diabetes Research and Clinical Practice, pages S54 - S59
Published online août-2013
To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Indonesian patients with type 2 diabetes (T2D) as part of the 24-week, international, prospective, non-interventional A1chieve study.
Indonesian patients who started BIAsp 30 were included. Safety and efficacy was measured as part of routine clinical practice at baseline, Week 12 and Week 24. Results: Overall, 1324 patients having a mean±SD age, duration of diabetes and body mass index of 55.2±9.9 yrs, 6.8±5.2 yrs and 24.1±3.6kg/m2, respectively, were enrolled. 67% of patients were insulin-naive and 33% were prior insulin users. Glycaemic control was poor at baseline. After 24 weeks, significant reductions from baseline were observed in the mean glycated haemoglobin A1c (HbA1c) (–2.6%), fasting plasma glucose (–93.8 mg/dL) and postprandial plasma glucose (–134.8 mg/dL) levels in the entire cohort (p < 0.001). Significant reductions were also seen in insulin-naive patients and prior insulin users. At Week 24, 29.9% of patients in the entire cohort achieved target HbA1c level of <7.0%, while 26.7% and 39.2% achieved this target among insulin-naive patients and prior insulin users, respectively. The proportion of patients reporting overall hypoglycaemia significantly decreased in the entire cohort after 24 weeks of BIAsp 30 therapy. A small significant increase in body weight was noted in the entire cohort, insulin-naive patients and prior insulin users.
The current study suggests that BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy in Indonesian patients with T2D.
Keywords: Type 2 diabetes, Indonesia, Biphasic insulin aspart 30, A1chieve.
© 2013 Published by Elsevier B.V.